Patients with optic disc swelling caused by nonarteritic anterior ischaemic optic neuropathy (NAION) have less light retardance compared with patients with optic disc swelling caused by papilloedema or optic neuritis.
Patients with optic disc swelling caused by nonarteritic anterior ischaemic optic neuropathy (NAION) have less light retardance compared with patients with optic disc swelling caused by papilloedema or optic neuritis.
For this cross-sectional study, researchers set out to compare retinal nerve fibre layer thickness (RNFLT) in patients with optic disc swelling of different etiologies, and included a total of 47 patients. Scanning laser polarimetry (SLP; enhanced corneal compensation) and spectral-domain optical coherence tomography (OCT) RNFLT measurements were done in 19 eyes with papilloedema, 10 eyes with optic neuritis, and 18 eyes with NAION.
They found no statistical differences on average OCT-RNFLT in papilloedema, optic neuritis, and NAION. The average SLP-RNFLT in patients with NAION was smaller compared with that measured in patients with papilloedema (P P = 0.02).
Comparisons of RNFLT in each retinal quadrant reveled no difference among the etiological groups upon OCT; upon SLP comparisons, however, the superior quadrant was found to be thinner in NAION patients compared with papilloedema or optic neuropathy patients (P P
Superior SLP-RNFLT in patients with NAION was smaller (P = 0.026). The ratio of average SLP-RNFLT to average OCT-RNFLT was smaller in patients with NAION compared with papilloedema (P = 0.001).
For more information on this study, click here.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials